Boston Scientific lowered its financial outlook as it anticipates a fourth-quarter sales decline, marking a difficult end to the year. The medical device maker cited a recent cyberattack and other operational challenges as key factors impacting its performance. The company now expects weaker revenue and profit margins than previously forecast, reflecting ongoing headwinds in the business environment.
Management has not provided a detailed timeline for recovery but emphasized that it is working to stabilize operations and mitigate further disruptions. The revised guidance underscores the growing impact of cybersecurity threats on corporate financial planning and supply chain resilience. Investors are closely monitoring the situation as Boston Scientific navigates both external pressures and internal adjustments to restore growth trajectory.
The update comes amid broader industry concerns about digital vulnerabilities and operational continuity in the healthcare sector.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing